D. E. Shaw & Co. Inc. cut its position in Zafgen Inc (NASDAQ:ZFGN) by 43.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 149,035 shares of the biopharmaceutical company’s stock after selling 113,857 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Zafgen were worth $738,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank of America Corp DE increased its position in Zafgen by 155.5% in the 4th quarter. Bank of America Corp DE now owns 19,909 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 12,116 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of Zafgen by 115.4% during the 4th quarter. Two Sigma Advisers LP now owns 30,800 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 16,500 shares during the period. Two Sigma Investments LP grew its position in shares of Zafgen by 19.7% during the 4th quarter. Two Sigma Investments LP now owns 119,108 shares of the biopharmaceutical company’s stock worth $590,000 after buying an additional 19,638 shares during the period. Geode Capital Management LLC grew its position in shares of Zafgen by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 420,983 shares of the biopharmaceutical company’s stock worth $2,083,000 after buying an additional 22,235 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Zafgen by 2.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 904,194 shares of the biopharmaceutical company’s stock worth $4,476,000 after buying an additional 21,423 shares during the period. Institutional investors and hedge funds own 86.74% of the company’s stock.

ZFGN has been the subject of several analyst reports. JMP Securities lifted their price target on shares of Zafgen from $8.00 to $17.00 and gave the stock a “hold” rating in a research report on Tuesday, March 12th. They noted that the move was a valuation call. Cowen reiterated a “hold” rating on shares of Zafgen in a research report on Thursday, January 17th. Leerink Swann upgraded shares of Zafgen from a “market perform” rating to an “outperform” rating and set a $4.52 price target for the company in a research report on Thursday, February 7th. Piper Jaffray Companies lowered their price target on shares of Zafgen from $18.00 to $6.00 and set a “hold” rating for the company in a research report on Monday, March 11th. Finally, Svb Leerink upgraded shares of Zafgen from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $9.45.

Shares of NASDAQ:ZFGN opened at $2.73 on Thursday. Zafgen Inc has a one year low of $2.57 and a one year high of $12.35. The company has a quick ratio of 9.12, a current ratio of 9.12 and a debt-to-equity ratio of 0.16. The company has a market cap of $108.59 million, a PE ratio of -1.44 and a beta of -0.41.

Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. As a group, equities research analysts forecast that Zafgen Inc will post -1.6 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zafgen Inc (ZFGN) Shares Sold by D. E. Shaw & Co. Inc.” was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/zafgen-inc-zfgn-shares-sold-by-d-e-shaw-co-inc/2954068.html.

Zafgen Profile

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Recommended Story: How to calculate compound interest

Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen Inc (NASDAQ:ZFGN).

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.